Insight journal - Company

Gilead Sciences: Partnering activity 2005-2013

Posted on 16 July 2013

Tags: , , ,

Gilead Sciences announced over 60 partnering / licensing deals since 2005, with 20 deals in 2006 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in infectives diseases.

Abstracted from: Report: Partnering Agreements with Gilead Sciences 2005-2013

The number of partnering, collaborative R&D and licensing deals announced varied year on year with a decline recently from 14 deals announced in 2011 to 2 deals last year. This was probably due to the effects of the 2008 economic crisis making companies more selective in their deal making as budgets were squeezed.

The following figure shows the level of Gilead Sciences partnering deal announcements since 2005.

Figure 1: Gilead Sciences partnering deals 2005-2013

Gilead deals per year

Source: Current Agreements, 2013

Analysis of the partnering deals shows a strong emphasis on partnerships in infectives disease area alone.

The following table provides an overview of the partnering deals announced by Gilead Sciences based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Agreements with Gilead Sciences 2005-2013

Figure 2: Gilead Sciences partnering deals by therapy area 2005-2013

Gilead deals by therapy

Source: Current Agreements, 2013

Further analysis of these deals shows that Gilead Sciences has a preference for licensing, manufacturing and distribution deals, unlike many other top pharmaceutical or big pharma companies who concentrate on collaborative R&D and development deal types. Such partnering deals provide the right for Gilead Sciences to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Gilead Sciences based on deal type disclosed.

Figure 3: Gilead Sciences partnering deals by deal type 2005-2013

Gilead deals by type

Source: Current Agreements, 2013

When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed with 26 deal announcements.

Gilead Sciences has an equal frequency distribution among discovery and preclinical stages of partnering and a fewer deals signed in clinical stage developments.

The following table provides an overview of the partnering deals announced by Gilead Sciences based on stage of development at signature.

Figure 4: Gilead Sciences partnering by stage of development 2005-2013

Gilead by stage development

Source: Current Agreements, 2013

Gilead Sciences has signed over 60 partnering, collaborative R&D and licensing deals since 2005. The following provides a summary of the top deals by headline value.

Figure 5: Top Gilead Sciences partnering deals by headline value 2005-2013

Gilead deals top by value

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal.

See: Partnering Agreements with Gilead Sciences 2005-2013

Gilead Sciences partnering at Current Agreements

View all partnering deals for Gilead Sciences: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Gilead Sciences 2005-2013

 

More

Summary profile data for Gilead Sciences

Partnering interests for Gilead Sciences

M&A activity for Gilead Sciences

 

Available reports from Current Partnering

Report: Partnering Agreements with Gilead Sciences 2005-2013

Report: Partnering Deals and Alliances with Big Pharma

 

Available resources for deal coverage for Gilead Sciences

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Gilead Sciences company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply